Correction: Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis
1. Reponex Pharmaceuticals receives regulatory approval for pivotal trial of RNX-011. 2. The trial targets serious peritonitis, a high-mortality condition. 3. RNX-011 aims to reduce complications in abdominal surgery. 4. Study results are critical for commercial partnerships and funding. 5. Pharma Equity Group emphasizes commitment to innovative medical solutions.